- Report
- July 2023
- 166 Pages
Global
From €5297EUR$5,500USD£4,555GBP
- Report
- March 2024
- 182 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- January 2024
- 69 Pages
Asia Pacific
From €2841EUR$2,950USD£2,443GBP
- Report
- December 2023
- 82 Pages
Europe
From €2841EUR$2,950USD£2,443GBP
- Report
- October 2023
- 377 Pages
Global
From €4045EUR$4,200USD£3,479GBP
- Report
- October 2023
- 155 Pages
Global
From €4334EUR$4,500USD£3,727GBP
- Report
- April 2024
- 185 Pages
Global
From €4719EUR$4,900USD£4,058GBP
- Report
- November 2022
- 155 Pages
Global
From €2167EUR$2,250USD£1,863GBP
- Report
- April 2024
- 185 Pages
From €4719EUR$4,900USD£4,058GBP
The EV Based Liquid Biopsy market is a rapidly growing segment of the pharmaceutical industry. It is a type of non-invasive diagnostic test that uses circulating cell-free extracellular vesicles (EVs) to detect and monitor cancer. EVs are released from cells into the bloodstream and can be used to detect cancer-specific biomarkers, providing a more accurate diagnosis than traditional methods. This technology has the potential to revolutionize cancer diagnosis and treatment, as it can detect cancer at an earlier stage and provide more precise information about the disease.
EV Based Liquid Biopsy is also being used to monitor the effectiveness of cancer treatments, as well as to detect and monitor other diseases such as cardiovascular disease and neurological disorders. This technology is being used in clinical trials and is expected to become more widely available in the near future.
Some companies in the EV Based Liquid Biopsy market include Exosome Diagnostics, Exosomics, Exosome Sciences, and Exosome Technologies. Show Less Read more